However, the association between low testosterone levels and grade group progression among men with prostate cancer managed on active surveillance remains unclear. This study, presented at the 2025 ...

There were 27 patients with 30 affected renal units identified, of which 13 renal units (43%) were treated with kidney-sparing surgery and UGN-101, and 17 renal units (57%) were treated with ...

Dr. Palacios concluded his presentation discussing the role of an intraoperative steep Trendelenburg break during robot-assisted laparoscopic radical prostatectomies with the following take-home ...

Neoadjuvant systemic therapy was acceptable to 70% of patients, with 69% of those willing to undergo renal mass biopsy first. While 52% would consider neoadjuvant systemic therapy for ≥16 weeks and 56 ...

Detalimogene voraplasmid is a novel, investigational, non-integrating, non-viral genetic medicine-based immunotherapy carrying a plasmid that simultaneously expresses IL-12 and regulators of RIG-I.

Intravesical cretostimogene is administered in combination with n-dodecyl-β-D-maltoside (DDM), an excipient that enhances adenoviral delivery, for 6 weekly doses during the induction phase, followed ...

The immune checkpoint inhibitor combination regimen has become the initial standard of care for metastatic RCC, given its significant survival benefit over sunitinib. Importantly, deferred nephrectomy ...

A total of 4,483 FDG PET/CTs were performed during the study period, of which 112 (2.5%) FDG PET/CTs incidentally revealed a FDG avid prostate lesion. There were 105 unique patients with incidental ...

The 2025 South Central AUA annual meeting included a session on urothelial cancer, featuring a presentation from Dr. Patrick Burnam discussing long-term outcomes of adjuvant UGN-101 in a real-world ...

Post-immune checkpoint inhibitor cytoreductive nephrectomy may be a safe and feasible treatment strategy in appropriately selected patients, with low rates of major intraoperative or post-operative ...

Cretostimogene grenadenorepvec is an oncolytic immunotherapy with a dual mechanism of action. It selectively replicates in and lyses bladder cancer cells with Rb-E2F pathway alterations. The ...

The 2025 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation from Dr. Horst Emanuel Lagos Beitz discussing the identification of predictive risk factors to ...